Medical Condition News

RSS

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.

7 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

Scientists discover key molecule that targets tumour blood vessels

Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

7 Jun 2011

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today reported updated data from a pivotal trial of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and a phase II trial in relapsed or refractory systemic anaplastic large cell lymphoma.

7 Jun 2011

Women with higher leptin levels have fewer symptoms of depression

Women who have higher levels of the appetite-controlling hormone leptin have fewer symptoms of depression, and this apparent inverse relationship is not related to body mass index (BMI), a new study finds.

7 Jun 2011

Specific forms of lymphoma create their own survival niche

Cancer cells do not grow equally well everywhere in the body. Often, they first create the conditions in which they can grow. Many years ago researchers discovered that solid tumors attract blood vessels to ensure their supply of nutrients by secreting specific factors.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Silencing two microRNAs may help treat age-related macular degeneration

Blocking two tiny molecules of RNA - a chemical cousin of DNA - appears to suppress the abnormal growth of blood vessels that occurs in degenerative eye disorders, UT Southwestern Medical Center researchers have found.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tragara Pharmaceuticals, Inc. announced today that apricoxib in combination with erlotinib demonstrated significant and consistent clinical benefit over erlotinib alone in a clinically relevant subset of biomarker-selected patients with non-small cell lung cancer (NSCLC) who had previously failed a platinum-containing regimen for advanced disease.

7 Jun 2011

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

According to the American Cancer Society, more than 11.4 million Americans are currently living with cancer. While cancer treatments are plentiful, many have negative side effects. Previous studies have indicated that a significant number of patients who receive chemotherapy also experience cognitive declines, including decreases in verbal fluency and memory.

7 Jun 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen announced today preliminary primary endpoint data on 12 of 20 patients enrolled in the first Phase 1 clinical trial with their lead cancer compound, Sym004.

7 Jun 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva Pharmaceutical Industries Ltd. announced today that lipegfilgrastim achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™).

7 Jun 2011

Researchers reveal surprising link between cell's skeleton and organ size

A group of scientists at the Instituto Gulbenkian de Ci-ncia, in Portugal, have uncovered a surprising link between the cell's skeleton and organ size. The team, led by Florence Janody, show in the journal Development, that one of the proteins that regulates the skeleton of the cell also acts to blocks activation of genes that promote cell survival and proliferation.

7 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

7 Jun 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

Celator Pharmaceuticals today announced positive clinical results in elderly patients with newly-diagnosed secondary acute myeloid leukemia (sAML) treated with CPX-351 Liposome Injection.

7 Jun 2011

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

3M Skin and Wound Care introduces 3M Kind Removal Silicone Tape with a new, silicone-based, adhesive technology that provides an optimal balance of securement and gentleness.

7 Jun 2011

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Scientists at Queen's University Belfast have discovered proteins in frog skins which could be used to treat cancer, diabetes, stroke and transplant patients by regulating the growth of blood vessels.

7 Jun 2011

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.

6 Jun 2011

Medical Condition News

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Scientists discover key molecule that targets tumour blood vessels

Millennium, Seattle Genetics' new brentuximab vedotin trial data presented at ASCO 2011

Women with higher leptin levels have fewer symptoms of depression

Specific forms of lymphoma create their own survival niche

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Silencing two microRNAs may help treat age-related macular degeneration

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Tragara's apricoxib-erlotinib Phase 2 study data on non-small cell lung cancer presented at ASCO 2011

Tai Chi may help overcome cognitive decline in patients receiving chemotherapy

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Researchers reveal surprising link between cell's skeleton and organ size

Homelessness and mental illness link explored in RMIT study

Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 2011

Positive results from Celator CPX-351 Phase 2b study on acute myeloid leukemia presented at ASCO

3M introduces Kind Removal Silicone Tape for patients with sensitive, at-risk skin

Frog skin proteins could treat cancer, diabetes and stroke: New discovery

Gleevec shows significant overall survival benefit for patients w/ GIST after 3 years of adjuvant treatment vs. 1 year

CoppaFeel!: Breast Cancer Doesn’t Discriminate, So Why Should Awareness?

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Latest News